

ENDOCYTE INC
Form 8-K
February 25, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 25, 2013

Endocyte, Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-35050 35-1969-140
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)

3000 Kent Avenue, Suite A1-100, West 47906
Lafayette, Indiana
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 765-463-7175

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 2.02 Results of Operations and Financial Condition.

On February 25, 2013, Endocyte, Inc. (the "Company") announced its results of operations for the three and twelve months ended December 31, 2012. A copy of the Company's earnings release is furnished herewith as Exhibit 99.1.

The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated February 25, 2013 relating to Endocyte's fourth quarter 2012 results of operations.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Endocyte, Inc.

*February 25, 2013 By: /s/ Michael A. Sherman
Name: Michael A. Sherman
Title: Chief Financial Officer*

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Exhibit 99.1 Earnings Release